Regulus Therapeutics Inc. (NASDAQ:RGLS) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research note issued to investors on Saturday. The brokerage presently has a $1.25 price objective on the biopharmaceutical company’s stock. Zacks Investment Research‘s target price indicates a potential downside of 4.58% from the company’s current price.

According to Zacks, “Regulus Therapeutics Inc. is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs, called microRNA therapeutics. The Company’s products aim to treat or prevent hepatitis C infections, cardiovascular disease, fibrosis, oncology, immuno-inflammatory diseases, and metabolic diseases. Regulus Therapeutics Inc. is based in La Jolla, California. “

A number of other equities analysts have also recently issued reports on the stock. Wedbush reiterated an “ourperform” rating and set a $4.00 price objective on shares of Regulus Therapeutics in a research report on Monday, August 7th. Needham & Company LLC reiterated a “hold” rating on shares of Regulus Therapeutics in a research report on Wednesday, August 2nd. Chardan Capital cut shares of Regulus Therapeutics from a “buy” rating to a “neutral” rating in a research report on Wednesday, August 2nd. BMO Capital Markets set a $1.00 price objective on shares of Regulus Therapeutics and gave the stock a “hold” rating in a research report on Monday, June 12th. Finally, ValuEngine cut shares of Regulus Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Friday, June 2nd. One research analyst has rated the stock with a sell rating, five have given a hold rating and two have issued a buy rating to the company’s stock. Regulus Therapeutics presently has an average rating of “Hold” and a consensus target price of $3.63.

Shares of Regulus Therapeutics (NASDAQ RGLS) opened at 1.31 on Friday. Regulus Therapeutics has a one year low of $0.79 and a one year high of $3.65. The firm’s market cap is $135.96 million. The company has a 50 day moving average of $0.99 and a 200-day moving average of $1.23.

Regulus Therapeutics (NASDAQ:RGLS) last released its quarterly earnings data on Tuesday, August 1st. The biopharmaceutical company reported ($0.41) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.31) by ($0.10). The company had revenue of $0.02 million for the quarter, compared to analyst estimates of $0.02 million. Regulus Therapeutics had a negative return on equity of 173.20% and a negative net margin of 31,460.47%. On average, analysts expect that Regulus Therapeutics will post ($1.02) EPS for the current year.

TRADEMARK VIOLATION NOTICE: “Regulus Therapeutics Inc. (RGLS) Upgraded at Zacks Investment Research” was reported by American Banking News and is the property of of American Banking News. If you are accessing this article on another domain, it was stolen and republished in violation of United States & international copyright & trademark legislation. The legal version of this article can be read at https://www.americanbankingnews.com/2017/09/16/regulus-therapeutics-inc-rgls-upgraded-at-zacks-investment-research.html.

In other Regulus Therapeutics news, insider Joseph P. Hagan purchased 219,780 shares of the firm’s stock in a transaction on Tuesday, July 25th. The stock was purchased at an average cost of $0.91 per share, for a total transaction of $199,999.80. Following the transaction, the insider now owns 241,297 shares in the company, valued at approximately $219,580.27. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director William H. Rastetter purchased 274,725 shares of the firm’s stock in a transaction on Tuesday, July 25th. The stock was acquired at an average price of $0.91 per share, with a total value of $249,999.75. The disclosure for this purchase can be found here. Over the last 90 days, insiders acquired 549,450 shares of company stock valued at $500,000. Corporate insiders own 4.80% of the company’s stock.

A number of hedge funds and other institutional investors have recently made changes to their positions in RGLS. Teachers Advisors LLC increased its position in Regulus Therapeutics by 15.7% in the 4th quarter. Teachers Advisors LLC now owns 72,273 shares of the biopharmaceutical company’s stock valued at $163,000 after acquiring an additional 9,804 shares during the period. Wells Fargo & Company MN increased its position in Regulus Therapeutics by 13.5% in the 1st quarter. Wells Fargo & Company MN now owns 782,380 shares of the biopharmaceutical company’s stock valued at $1,291,000 after acquiring an additional 93,295 shares during the period. South Dakota Investment Council increased its position in Regulus Therapeutics by 16.3% in the 1st quarter. South Dakota Investment Council now owns 1,327,058 shares of the biopharmaceutical company’s stock valued at $2,190,000 after acquiring an additional 186,130 shares during the period. Tudor Investment Corp ET AL increased its position in Regulus Therapeutics by 131.5% in the 1st quarter. Tudor Investment Corp ET AL now owns 108,061 shares of the biopharmaceutical company’s stock valued at $178,000 after acquiring an additional 61,373 shares during the period. Finally, Wedbush Securities Inc. increased its position in Regulus Therapeutics by 10.3% in the 2nd quarter. Wedbush Securities Inc. now owns 199,521 shares of the biopharmaceutical company’s stock valued at $197,000 after acquiring an additional 18,600 shares during the period. Hedge funds and other institutional investors own 21.93% of the company’s stock.

About Regulus Therapeutics

Regulus Therapeutics Inc is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs to treat a range of diseases. The Company uses its microRNA product platform to develop chemically modified, single-stranded oligonucleotides that the Company calls anti-miRs to modulate microRNAs and return diseased cells to their healthy state.

Get a free copy of the Zacks research report on Regulus Therapeutics (RGLS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Regulus Therapeutics (NASDAQ:RGLS)

Receive News & Ratings for Regulus Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regulus Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.